EP3976068A4 - Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t - Google Patents

Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t Download PDF

Info

Publication number
EP3976068A4
EP3976068A4 EP20814747.0A EP20814747A EP3976068A4 EP 3976068 A4 EP3976068 A4 EP 3976068A4 EP 20814747 A EP20814747 A EP 20814747A EP 3976068 A4 EP3976068 A4 EP 3976068A4
Authority
EP
European Patent Office
Prior art keywords
cell subsets
selective expansion
cytokine cocktails
cocktails
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20814747.0A
Other languages
German (de)
English (en)
Other versions
EP3976068A1 (fr
Inventor
Catherine Mary BOLLARD
Patrick Hanley
Christopher LAZARSKI
Michael Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens National Medical Center Inc
Original Assignee
Childrens National Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens National Medical Center Inc filed Critical Childrens National Medical Center Inc
Publication of EP3976068A1 publication Critical patent/EP3976068A1/fr
Publication of EP3976068A4 publication Critical patent/EP3976068A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
EP20814747.0A 2019-05-31 2020-06-01 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t Pending EP3976068A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855889P 2019-05-31 2019-05-31
PCT/US2020/035618 WO2020243729A1 (fr) 2019-05-31 2020-06-01 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t

Publications (2)

Publication Number Publication Date
EP3976068A1 EP3976068A1 (fr) 2022-04-06
EP3976068A4 true EP3976068A4 (fr) 2023-08-09

Family

ID=73553344

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20814747.0A Pending EP3976068A4 (fr) 2019-05-31 2020-06-01 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t

Country Status (2)

Country Link
EP (1) EP3976068A4 (fr)
WO (1) WO2020243729A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201851A1 (fr) * 2020-12-09 2022-06-16 Ryan SAADI Lymphocytes t specifiques d'un virus et procedes de traitement et de prevention d'infections virales
WO2022195096A1 (fr) * 2021-03-19 2022-09-22 Charité - Universitätsmedizin Berlin Peptide et procédé d'analyse directe de réponses immunitaires au sras-cov-2
WO2022212505A1 (fr) * 2021-03-30 2022-10-06 Arizona Board Of Regents On Behalf Of Arizona State University Production optimale de particules pseudovirales (vlp) du sars-cov-2 produites dans des cellules de mammifère
WO2023034958A1 (fr) * 2021-09-03 2023-03-09 Dupont Nutrition Biosciences Aps Antigènes microbiens à réactivité croisée destinés à être utilisés dans la stimulation de lymphocytes t
CN114578048B (zh) * 2021-12-22 2023-08-08 重庆医科大学附属儿童医院 一种t淋巴细胞发育亚群免疫分型的方法和试剂盒
GR1010557B (el) * 2022-05-04 2023-10-16 Νοσοκομειο Γεωργιος Παπανικολαου, Sars-cov-2-ειδικα τ λεμφοκυτταρα για θεραπεια της covid-19
CN116694828A (zh) * 2023-08-01 2023-09-05 北京大学人民医院 检测试剂的应用、cd3+t细胞抗感染能力评估方法及产品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (fr) * 2012-02-09 2013-08-15 Baylor College Of Medicine Mélange de peptides pour produire des ctlmultiviraux avec une large spécificité
WO2017049291A1 (fr) * 2015-09-18 2017-03-23 Baylor College Of Medicine Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique
WO2017075571A1 (fr) * 2015-10-30 2017-05-04 Children's National Medical Center Génération de lymphocytes t spécifiques contre l'antigène du vph à partir d'une population de lymphocytes t naïfs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178885A1 (en) * 2009-08-24 2012-04-27 Baylor College Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
EP2532740A1 (fr) * 2011-06-11 2012-12-12 Michael Schmück Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
CN114107197A (zh) * 2015-05-13 2022-03-01 泰尔茂比司特公司 细胞扩增
US20200237819A1 (en) * 2016-06-28 2020-07-30 Geneius Biotechnology, Inc. T cell compositions for immunotherapy
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (fr) * 2012-02-09 2013-08-15 Baylor College Of Medicine Mélange de peptides pour produire des ctlmultiviraux avec une large spécificité
WO2017049291A1 (fr) * 2015-09-18 2017-03-23 Baylor College Of Medicine Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique
WO2017075571A1 (fr) * 2015-10-30 2017-05-04 Children's National Medical Center Génération de lymphocytes t spécifiques contre l'antigène du vph à partir d'une population de lymphocytes t naïfs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020243729A1 *

Also Published As

Publication number Publication date
WO2020243729A1 (fr) 2020-12-03
EP3976068A1 (fr) 2022-04-06

Similar Documents

Publication Publication Date Title
EP3976068A4 (fr) Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t
EP3976057A4 (fr) Dosage de lymphocytes t ayant subi une expansion
EP3874030A4 (fr) Compositions et procédés pour l'ingénierie des lymphocytes t
EP3949998A4 (fr) Activateur cellulaire
EP4054765A4 (fr) Systèmes microfluidiques numériques, appareils et procédés d'utilisation de ceux-ci
EP3909590A4 (fr) Association pour immunothérapie cellulaire
EP4048293A4 (fr) Systèmes et procédés de culture cellulaire
EP3992204A4 (fr) Cellule pour résister à une réaction de greffe et procédé
IL282110A (en) A method for activating/cultivating T cells
EP3950930A4 (fr) Composition de milieu de culture
EP3747433A4 (fr) Association d'immunothérapie cellulaire
IL290590A (en) Methods for growing cells
EP4077282A4 (fr) Inhibiteurs de prmt5
EP3955528A4 (fr) Procédé de mesure de retard, système et support de stockage
EP3999626A4 (fr) Procédés de culture de cellules souches pour obtenir des produits et leurs modes de réalisation
IL290433A (en) Mutations of interleukin-2 for the expansion of regulatory t cells
EP3816279A4 (fr) Additif pour culture de cellules souches, milieu de culture, et méthode de culture
EP4065709A4 (fr) Expansion sélective de cellules ciblées par un gène
EP3719120A4 (fr) Méthode de culture de cellules
EP4076459A4 (fr) Inhibiteurs de prmt5
EP3946426A4 (fr) Procédé d'amélioration de l'immunothérapie cellulaire
EP3895328A4 (fr) Procédés et systèmes destinés à adapter la largeur de faisceau de faisceaux sur des canaux physiques nr
EP3871444A4 (fr) Systèmes et procédés de sélection et resélection de cellules
EP4055988A4 (fr) Système et procédé pour de multiples réceptions discontinues pour un groupe de cellules
EP3815549A4 (fr) Gyoza congelé et son procédé de production

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230707

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230704BHEP

Ipc: C07K 14/54 20060101ALI20230704BHEP

Ipc: C07K 14/005 20060101ALI20230704BHEP

Ipc: A61K 39/215 20060101ALI20230704BHEP

Ipc: A61K 39/12 20060101ALI20230704BHEP

Ipc: A61K 38/00 20060101ALI20230704BHEP

Ipc: A61K 35/17 20150101AFI20230704BHEP